Hamanaka Mie, Yamano Tomoki, Noda Masafumi, Tsukamoto Kiyoshi, Kuno Takashi, Yamagishi Daisuke, Babaya Akihito, Matsubara Nagahide, Kamikonya Norihiko, Tomita Naohiro
Division of Lower Gastrointestinal Surgery, Dept. of Surgery, Hyogo College of Medicine.
Gan To Kagaku Ryoho. 2011 Nov;38(12):2253-5.
A 52-year-old woman diagnosed with lower rectal cancer was referred to our hospital for the operation of anal sphincter preservation. Rectal examination and colonoscopy showed a type 2 semicircular tumor on the posterior wall at 4 .5-7 cm from anal verge with incomplete mobility (cT3). She was diagnosed as the moderately differentiated tubular adenocarcinoma by biopsy. Computed tomography and magnetic resonance imaging showed no sign of invasion to the surrounding organs and metastasis to lymph nodes or the other organs (cN0, cM0). We performed a preoperative chemoradiotherapy (CRT) combined with S-1 and CPT-11. Radiation (1.8 Gy) was administered a total of 45 Gy( day 1-5, 8-12, 15-19, 22-26, 29-33). S-1 was taken orally( 100 mg/day: day 1-5, 8-12, 22-26, 29-33), and CPT-11 was administered intravenously (60 mg/m²: day 1, 8, 22, 29). Endoscopy after CRT showed a reduction of the tumor size (from semicircular to quarter-circular) and lowering of marginal wall. Rectal examination revealed an improvement of tumor mobility. Eight weeks after CRT, the patient underwent ISR with partial ESR and covering ileostomy pathological examination demonstrated no residual cancer cell in the primary lesion and lymph node (Grade 3, pCR). Preoperative CRT can be a promising tool for locally advanced rectal cancer.
一名52岁被诊断为低位直肠癌的女性因保留肛门括约肌手术转诊至我院。直肠指检和结肠镜检查显示,距肛缘4.5 - 7 cm处后壁有一个2型半圆形肿瘤,活动度欠佳(cT3)。活检诊断为中分化管状腺癌。计算机断层扫描和磁共振成像显示无周围器官侵犯及淋巴结或其他器官转移迹象(cN0,cM0)。我们进行了术前同步放化疗(CRT),联合使用S - 1和CPT - 11。放疗(1.8 Gy)共给予45 Gy(第1 - 5天、8 - 12天、15 - 19天、22 - 26天、29 - 33天)。S - 1口服(100 mg/天:第1 - 5天、8 - 12天、22 - 26天、29 - 33天),CPT - 11静脉注射(60 mg/m²:第1天、8天、22天、29天)。CRT后内镜检查显示肿瘤大小减小(从半圆形变为四分之一圆形),边缘壁降低。直肠指检显示肿瘤活动度改善。CRT 8周后,患者接受了ISR联合部分ESR及覆盖式回肠造口术,病理检查显示原发灶和淋巴结无残留癌细胞(3级,pCR)。术前CRT可能是局部晚期直肠癌的一种有前景的治疗手段。